Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 9/20 | 0.44 |
| ▸ | CDK1 | P06493 | 9/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 8/20 | 0.43 |
| ▸ | GSK3B | P49841 | 8/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941364 | 0.83 | MAPK14 (0.52) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL4937417 | 0.77 | CCNB2 (0.43) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL4940959 | 0.77 | CCNB2 (0.46) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL14545142 | 0.76 | CCNB2 (0.45) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL4934478 | 0.76 | ALDH1A1 (0.50) | GSK3AGSK3BMEN1GAAMAPT | |
| SCHEMBL4940389 | 0.76 | NEK1 (0.45) | GSK3AGSK3BMAPTMAPK14CYP3A4 | |
| SCHEMBL4933913 | 0.76 | RAB9A (0.47) | GSK3BMEN1GAAMAPTKMT2A | |
| SCHEMBL4939133 | 0.75 | PTGS2 (0.49) | CCNB2CDK1CCNB1CCNB3GSK3A | |
| SCHEMBL4930977 | 0.75 | TBK1 (0.57) | GSK3AGSK3BMEN1GAAMAPT | |
| SCHEMBL4935159 | 0.74 | MEN1 (0.41) | CCNB2CDK1CCNB1CCNB3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | CCNB2 1437/4885CDK1 42/4885CCNB1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.